Cover Image
Market Research Report
Product code 
1064081

Flow Cytometry Services Market by Type of General Flow Cytometric Services (Assay Development and Consumables Manufacturing), Type of Analysis based Flow Cytometric Services (PBMC Analysis, Whole Blood Cells Analysis,

Published: | Roots Analysis | 230 Pages | Delivery time: 1-2 business days

Price

Back to Top
Flow Cytometry Services Market by Type of General Flow Cytometric Services (Assay Development and Consumables Manufacturing), Type of Analysis based Flow Cytometric Services (PBMC Analysis, Whole Blood Cells Analysis,
Published: February 28, 2022
Roots Analysis
Content info: 230 Pages
Delivery time: 1-2 business days
  • Description
  • Table of Contents
  • List of Tables

Title:
Flow Cytometry Services
Market by Type of General Flow Cytometric Services (Assay Development and Consumables Manufacturing), Type of Analysis based Flow Cytometric Services (PBMC Analysis, Whole Blood Cells Analysis, Bone Marrow Aspirate Analysis, Stem Cells Analysis, Rare Cells Detection, Cell Profiling and Subsetting and Intracellular Staining), Other types of Flow Cytometric Services, Type of Accreditations (Government and Third-Party Accreditations), Key Players, and Key Geographical Regions (North America, Europe, Asia Pacific and Rest of the World): Industry Trends and Global Forecasts, 2022-2035.

Example Insights:

Overview:

First introduced in 1950s, the flow cytometry technique has gained significant attention in the past few decades. This can be attributed to the fact that flow cytometry has been demonstrated to be capable of overcoming various challenges associated with conventional analytical techniques, such as western blotting and immunohistochemistry. The key concerns related to traditional approaches include low specificity and sensitivity, time and cost intensive procedures, higher chances of producing false results. Specifically, flow cytometry offers several advantages over the conventional methods intended for single cell analysis. For instance, using microscopy, about 6 parameters of a single cell can be detected, whereas a flow cytometer enables the detection of up to 30 distinct parameters. In addition, the modern flow cytometer is capable of processing over 10,000 cells per second, thereby, enabling scientists to rapidly analyze and characterize millions of cells. Currently, flow cytometry is used in a number of applications in the medical industry, including assisting in evaluation of autoimmune disorders and infectious diseases, and diagnosis of leukemia and lymphoma. The increasing prevalence of chronic conditions has led to a rise in the number of focused research efforts being carried out; this has further created a considerable demand for advanced and rapid analytical techniques to better understand the disease morphology. In this context, the adoption of flow cytometry technique has witnessed considerable growth. However, this approach often requires the use of complex and expensive instruments, which need to be operated by highly trained professionals. Several small and mid-sized players usually do not have the resources to make such exorbitant investments. Therefore, outsourcing has emerged as a preferred operational model for flow cytometry innovators, who rely on specialty contract service providers to handle various aspects of flow cytometry related services.

At present, 30 players claim to offer a range of flow cytometry related services, including customized assay development services, manufacturing of consumables (such as dyes and buffers) used for analysis, analysis of various immune cells for various clinical and non-clinical studies, and cell line development. Further, 25 companies are currently engaged in the manufacturing of novel and advanced flow cytometers. To keep pace with the increasing demand for such services, players are not only actively undertaking initiatives to improve / expand their existing offerings but also entering into strategic partnerships with several industry stakeholders to broaden their respective services portfolios. For instance, in April 2021, Agilex Biolabs acquired TetraQ in order to further broaden its portfolio for analytical services offered via flow cytometry. Driven by the increasing number of clinical studies focused on evaluating treatment modalities against chronic disorders, we believe that the flow cytometry services market is likely to evolve at a steady pace in the foreseen future.

Scope of the Report:

The "Flow Cytometry Services Market by Type of General Flow Cytometric Services (Assay Development and Consumables Manufacturing), Type of Analysis based Flow Cytometric Services (PBMC Analysis, Whole Blood Cells Analysis, Bone Marrow Aspirate Analysis, Stem Cells Analysis, Rare Cells Detection, Cell Profiling and Subsetting and Intracellular Staining), Other types of Flow Cytometric Services, Type of Accreditations (Government and Third-Party Accreditations), Key Players, and Key Geographical Regions (North America, Europe, Asia Pacific and Rest of the World): Industry Trends and Global Forecasts, 2022-2035" , report features an extensive study on the current market landscape, offering an informed opinion on the likely evolution of flow cytometry service providers market, in the mid to long term. The study includes an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field. In addition to other elements, the report includes:

  • A detailed review of the overall market landscape of the flow cytometry service providers, based on several relevant parameters, such as year of establishment, company size, location of headquarters, location of flow cytometry facilities, type of service(s) offered (general services, analysis services and other flow cytometric services). In addition, the chapter also provides information on the manufacturers and the respective flow cytometry equipment developed / being developed by them.
  • A detailed competitiveness analysis of the flow cytometry service providers based across different geographies, by taking into consideration their service strength (based on number of services offered), accreditations (based on number of government and third-party accreditations) and supplier strength (based on total years of experience in the industry and company size).
  • Tabulated profiles of key players offering services related to flow cytometry, based across various geographies. Each profile includes a brief overview of the company, financial information (if available), details on its services portfolio, types of services offered, location of flow cytometry facilities, recent developments and an informed future outlook.
  • An analysis of the partnerships that have been inked by various stakeholders engaged in the field of flow cytometry, during the period 2011-2021, covering product development agreements, research and development agreements, licensing agreements, product commercialization agreements, platform utilization agreement, technology integration agreements and other relevant types of deals.

One of the key objectives of the report was to identify the primary growth drivers and estimate the future growth opportunity associated with the flow cytometry services market. We have provided an informed estimate of the evolution of the market for the period 2022-2035. Our year-wise projections of the current and future opportunity have further been segmented on the basis of region (North America, Europe and Asia-Pacific). In order to account for the uncertainties and to add robustness to our model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.

The opinions and insights presented in the report are backed by a deep understanding of key insights generated from our secondary research.

All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered:

  • Who are the leading players offering services related to flow cytometry?
  • What is the relative competitiveness of the players offering services related to flow cytometry, based across different geographies?
  • What are the type of services being offered by players engaged in the field of flow cytometry?
  • What are the key trends in the flow cytometry service providers market?
  • What kind of initiatives are being taken by stakeholders engaged in the flow cytometry domain?
  • How is the current and future opportunity likely to be distributed across key market segments?

Chapter Outlines:

Chapter 1 is an executive summary of the insights captured in our research. It offers a high-level view on the current state of the flow cytometry services market and its likely evolution in the mid to long term.

Chapter 2 provides a general introduction to flow cytometry and types of flow cytometers. In addition, the chapter highlights the importance of flow cytometry and challenges associated with the use of flow cytometers. Further, it provides a brief introduction on the types of services offered by the players, discussing the role of contract service providers in the field of flow cytometry, prevalent outsourcing trends and future perspectives.

Chapter 3 provides an overview of the overall market landscape of flow cytometry service providers, featuring a list of around 30 stakeholders and a detailed analysis based on several parameters, such as year of establishment, company size, location of headquarters, location of flow cytometry facilities, type of general services offered (customized assay development and consumables manufacturing), type of analysis based services offered (PBMC analysis, whole blood cell analysis, bone marrow aspirate analysis, stem cells analysis, intra-cellular staining, rare cell detection and cell profiling and subsetting), other types of flow cytometric services offered and type of accreditations (FDA, EMA, TGA, PMDA and others).

Chapter 4 presents an insightful competitiveness analysis of the flow cytometry service providers based across different geographies, by taking into consideration their service strength (based on number of services offered), supplier strength (based on total years of experience in this industry and company size) and accreditations (based on number of government and third-party accreditations).

Chapter 5 includes tabulated profiles of key players offering services related to flow cytometry, based in North America. Each profile includes a brief overview of the company, financial information (if available), details on its services portfolio, location of flow cytometry facilities, recent developments, and an informed future outlook.

Chapter 6 includes tabulated profiles of key players offering services related to flow cytometry, based in Europe. Each profile includes a brief overview of the company, financial information (if available), details on its services portfolio, location of flow cytometry facilities, recent developments, and an informed future outlook.

Chapter 7 includes tabulated profiles of key players offering services related to flow cytometry, based in the Asia-Pacific region. Each profile includes a brief overview of the company, financial information (if available), details on its services portfolio, location of flow cytometry facilities, recent developments, and an informed future outlook.

Chapter 8 features a detailed analysis of the partnerships and collaborations that have been inked in this domain since 2011, covering product development agreements, research and development agreements, licensing agreements, product commercialization agreements, platform utilization agreements, technology integration agreements and other relevant types of deals.

Chapter 9 features an in-depth efficiency comparison analysis of seven analogous conventional techniques of flow cytometry, on the basis of important parameters, such as analytical strength, time duration score and accuracy strength.

Chapter 10 presents an insightful market forecast analysis, highlighting the likely growth of the flow cytometry services market for the period, 2022-2035. In order to provide a detailed future outlook, our year-wise projections of the current and future opportunity have further been segmented on the basis of region (North America, Europe and Asia-Pacific).

Chapter 11 is a summary of the overall report, presenting key insights on the contemporary market trends and the likely evolution of the flow cytometry services market.

Chapter 12 is an appendix that contains tabulated data and numbers for all the figures in the report.

Chapter 13 is an appendix that provides the list of companies and organizations mentioned in the report.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Key Questions Answered
  • 1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Introduction to Flow Cytometry
  • 3.3. Flow Cytometry Versus Conventional Analytical Techniques
  • 3.4. Difference between Flow Cytometer, Cell Analyzer and Cell Sorter
  • 3.5. Flow Cytometry Instrumentation
    • 3.5.1. Flow Cytometry Technologies
    • 3.5.2. Flow Cytometry: Cell Analyzing and Counting Methodology
    • 3.5.3. Flow Cytometry: Software and Automation Support
  • 3.6. Flow Cytometry Services
    • 3.6.1 Flow Cytometric Analysis
    • 3.6.2. Flow Cytometric Consumables and Assay Development
  • 3.7 Future Perspectives

4. MARKET LANDSCAPE

  • 4.1. Chapter Overview
  • 4.2. Flow Cytometry Service Providers: Overall Market Landscape
    • 4.2.1. Analysis by Year of Establishment
    • 4.2.2. Analysis by Company Size
    • 4.2.3. Analysis by Region wise Distribution of Companies
    • 4.2.4. Analysis by Location of Flow Cytometry Facilities
  • 4.3. Analysis by Type(s) of Service Offered
    • 4.3.1. Analysis by Type(s) of Flow Cytometric Services Offered
    • 4.3.2. Analysis by Type(s) of Analytical Flow Cytometric Services Offered
  • 4.4. Analysis by Type(s) of Instrument Providers

5. COMPANY COMPETITIVENESS ANALYSIS

  • 5.1. Chapter Overview
  • 5.2. Methodology
  • 5.3. Key Parameters
  • 5.4. Competitiveness Analysis: Flow Cytometry Service Providers
    • 5.4.1. Flow Cytometry Service Providers in North America
    • 5.4.2 Flow Cytometry Service Providers in Europe and Asia-Pacific

6. COMPANY PROFILES: FLOW CYTOMETRY SERVICE PROVIDERS IN NORTH AMERICA

  • 6.1. Chapter Overview
  • 6.2. FlowMetric Life Sciences
    • 6.2.1. Company Overview
    • 6.2.2. Flow Cytometry Services Portfolio
    • 6.2.3. Recent Developments and Future Outlook
  • 6.3. Flow Contract Sites Laboratory
    • 6.3.1. Company Overview
    • 6.3.2. Flow Cytometry Services Portfolio
    • 6.3.3. Recent Developments and Future Outlook
  • 6.4. Bio-Legend
    • 6.4.1. Company Overview
    • 6.4.2. Flow Cytometry Services Portfolio
    • 6.4.3. Recent Developments and Future Outlook
  • 6.5. Q2 Solutions
    • 6.5.1. Company Overview
    • 6.5.2. Flow Cytometry Services Portfolio
    • 6.5.3. Recent Developments and Future Outlook

7. COMPANY PROFILES: FLOW CYTOMETRY SERVICE PROVIDERS IN EUROPE

  • 7.1. Chapter Overview
  • 7.2. ProImmune
    • 7.2.1. Company Overview
    • 7.2.2. Flow Cytometry Services Portfolio
    • 7.2.3. Recent Developments and Future Outlook
  • 7.3. MLM Medical Labs
    • 7.3.1. Company Overview
    • 7.3.2. Flow Cytometry Services Portfolio
    • 7.3.3. Recent Developments and Future Outlook
  • 7.4. Unilabs
    • 7.4.1. Company Overview
    • 7.4.2. Flow Cytometry Services Portfolio
    • 7.4.3. Recent Developments and Future Outlook
  • 7.5. Firalis
    • 7.5.1. Company Overview
    • 7.5.2. Flow Cytometry Services Portfolio
    • 7.5.3. Recent Developments and Future Outlook

8. COMPANY PROFILES: FLOW CYTOMETRY SERVICE PROVIDERS IN ASIA-PACIFIC

  • 8.1. Agilex Biolabs
    • 8.1.1. Company Overview
    • 8.1.2. Flow Cytometry Services Portfolio
    • 8.1.3. Recent Developments and Future Outlook

9. PARTNERSHIPS AND COLLABORATIONS

  • 9.1. Chapter Overview
  • 9.2. Partnership Models
    • 9.2.1. Flow Cytometry Service Providers: List of Partnerships and Collaborations
    • 9.2.2. Analysis by Year of Partnership
    • 9.2.3. Analysis by Type of Partnership
    • 9.2.4. Analysis by Type of Partner
  • 9.3. Flow Cytometry Service Providers: Information on Type of Service(s) Offered
    • 9.3.1. Analysis by Type of Service Offered
    • 9.3.2. Analysis by Type of Service Offered and Type of Partnership
    • 9.3.3. Most of Active Players: Analysis by Number of Partnerships
    • 9.3.4. Top Partners: Analysis by Number of Partnerships
    • 9.3.5. Geographical Analysis: Intercontinental and Intracontinental Agreements

10. EFFICIENCY COMPARISON MODULE

  • 10.1 Chapter Overview
  • 10.2 Methodology
  • 10.3 Key Parameters
  • 10.4 Flow Cytometry Efficiency Comparison Analysis
  • 10.5 Inclusive Efficiency Comparison Analysis
  • 10.6 Efficiency Comparison Analysis
    • 10.6.1 Flow Cytometry vs Immunohistochemistry
    • 10.6.2 Flow Cytometry and Cytogenetics Testing
    • 10.6.3 Flow Cytometry and Fluorescence Microscopy
    • 10.6.4 Flow Cytometry and ELISA
    • 10.6.5 Flow Cytometry and Western Blotting
    • 10.6.6 Flow Cytometry and Hematology Cell Analyzer
    • 10.6.7 Flow Cytometry and Dynabead Method
  • 10.7 Concluding Remarks

11. MARKET FORECAST

  • 11.1 Chapter Overview
  • 11.2 Forecast Methodology and Key Assumptions
  • 11.3 Flow Cytometry Services Market in North America, 2022-2035
  • 11.4 Flow Cytometry Services Market in Europe, 2022-2035
  • 11.5 Flow Cytometry Services Market in Asia-Pacific, 2022-2035

12. CONCLUDING REMARKS

  • 12.1. Chapter Overview

13. APPENDIX 1: TABULATED DATA

14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

  • Figure 3.1 Working Mechanism of Flow Cytometry
  • Figure 3.2 Difference between Flow Cytometer, Cell Analyzer and Cell Sorter
  • Figure 3.3 Flow Cytometry: Based on Type of Technology
  • Figure 3.4 Services related to Flow Cytometry
  • Figure 4.1 Flow Cytometry Service Providers: Distribution by Year of Establishment
  • Figure 4.2 Flow Cytometry Service Providers: Distribution by Company Size
  • Figure 4.3 Flow Cytometry Service Providers: Region wise Distribution of Companies
  • Figure 4.4 Flow Cytometry Service Providers: Distribution by Location of Flow Cytometry Facilities
  • Figure 4.5 Flow Cytometry Service Providers: Distribution by Type of Services Offered
  • Figure 4.6 Flow Cytometry Service Providers: Distribution by Type of General Flow Cytometry Services Offered
  • Figure 4.7 Flow Cytometry Service Providers: Distribution by Type of Analysis based Flow Cytometry Services Offered
  • Figure 4.8 Flow Cytometry Service Providers: Distribution by Type of Instrument Used
  • Figure 5.1 Company Competitiveness Analysis: Flow Cytometry Service Providers in North America
  • Figure 5.2 Company Competitiveness Analysis: Flow Cytometry Service Providers in Europe and Asia Pacific
  • Figure 9.1 Partnerships and Collaborations: Cumulative Year Wise Trend: 2010-2021 (till July)
  • Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 9.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2010-2021 (till July)
  • Figure 9.4 Partnerships and Collaborations: Distribution by Type of Partner
  • Figure 9.5 Partnerships and Collaborations: Distribution by Type of Service Offered
  • Figure 9.6 Partnerships and Collaborations: Distribution by Type of Service Offered and Type of Partnership
  • Figure 9.7 Most Active Players: Distribution by Number of Partnerships
  • Figure 9.8 Top Partners: Distribution by Number of Partnerships
  • Figure 9.9 Partnerships and Collaborations: Geographical Analysis
  • Figure 9.10 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements

List Of Tables

  • Table 4.1 Flow Cytometry Service Providers: List of Companies
  • Table 4.2 Flow Cytometry Services Providers: Type of Service(s) Offered
  • Table 6.1 Flow Cytometry Service Providers in North America: List of Companies Profiled
  • Table 6.2 Flowmetric Life Sciences: Company Snapshot
  • Table 6.3 Flowmetric Life Sciences: Services Portfolio
  • Table 6.4 Flowmetric Life Sciences: Recent Developments and Future Outlook
  • Table 6.5 Flow Contract Site Laboratories: Company Snapshot
  • Table 6.6 Flow Contract Site Laboratories: Services Portfolio
  • Table 6.7 Flow Contract Site Laboratories: Recent Developments and Future Outlook
  • Table 6.8 Bio-Legend: Company Snapshot
  • Table 6.9 Bio-Legend: Services Portfolio
  • Table 6.10 Bio-Legend: Recent Developments and Future Outlook
  • Table 6.11 Q2 Solutions: Company Snapshot
  • Table 6.12 Q2 Solutions: Services Portfolio
  • Table 6.13 Q2 Solutions: Recent Developments and Future Outlook
  • Table 7.1 Flow Cytometry Service Providers in Europe: List of Companies Profiled
  • Table 7.2 ProImmune: Company Snapshot
  • Table 7.3 ProImmune: Services Portfolio
  • Table 7.4 ProImmune: Recent Developments and Future Outlook
  • Table 7.5 MLM Medical Labs: Company Snapshot
  • Table 7.6 MLM Medical Labs: Services Portfolio
  • Table 7.7 MLM Medical Labs: Recent Developments and Future Outlook
  • Table 7.8 Unilabs: Company Snapshot
  • Table 7.9 Unilabs: Services Portfolio
  • Table 7.10 Unilabs: Recent Developments and Future Outlook
  • Table 7.11 Firalis: Company Snapshot
  • Table 7.12 Firalis: Services Portfolio
  • Table 7.13 Firalis: Recent Developments and Future Outlook
  • Table 8.1 Flow Cytometry Service Providers in Asia-Pacific: List of Companies Profiled
  • Table 8.2 Agilex Biolabs: Company Snapshot
  • Table 8.3 Agilex Biolabs: Services Portfolio
  • Table 8.4 Agilex Biolabs: Recent Developments and Future Outlook
  • Table 9.1 Flow Cytometry Service Providers: List of Partnerships and Collaborations
  • Table 9.2 Flow Cytometry Service Providers: Information on Type of Service(s) offered

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  • 1. ABS Laboratories
  • 2. Accelix
  • 3. Accuri Cytometers
  • 4. ACEA Bioscience (Acquired by Agilent Technologies)
  • 5. ACM Global Laboratories
  • 6. Affymetrix (Acquired by Thermofisher Scientific)
  • 7. Agilent Technologies
  • 8. Agilex Biolabs
  • 9. AH diagnostics
  • 10. Akadeum Life Science
  • 11. AllCells
  • 12. Alverno Laboratories
  • 13. Amphasys
  • 14. ApogeeFlow
  • 15. BD
  • 16. Beckman Coulter
  • 17. Bio Legend
  • 18. bioMérieux
  • 19. Bio-Rad laboratories
  • 20. Blue Ocean Biomedical (Acquired by Beckman Coulter)
  • 21. Bucher Biotec
  • 22. Caprion Biosciences
  • 23. CellCarta
  • 24. Cellular Research
  • 25. CirQuest Labs (Acquired by MLM Medical Labs)
  • 26. Clearstone Central Laboratories
  • 27. CSI Laboratories
  • 28. Cytek Bioscience s
  • 29. Cytobank
  • 30. Cytognos
  • 31. Cytonome
  • 32. Cytonome
  • 33. DAON Biosciences
  • 34. De Novo Software
  • 35. Discovery and Drug Development Solutions (Division of Merck Millipore)
  • 36. Discovery Life Sciences
  • 37. EMBL
  • 38. Eurofins Bioanalytical Services
  • 39. Filgen
  • 40. Firalis
  • 41. Flow Contract Site Laboratory (FCSL)
  • 42. Flow Jo
  • 43. Flow Paradigm
  • 44. FlowMetric Life Sciences
  • 45. Genoptix
  • 46. Handeym
  • 47. Hematogenix
  • 48. HepaTX
  • 49. I&L Biosystems
  • 50. ICON Speciality Labs (formerly known as MolecularMD)
  • 51. iCyt Mission Technology
  • 52. Inabata
  • 53. IncellDX
  • 54. Invetech
  • 55. Invitrx Therapeutics
  • 56. KCAS Bioanlytical and Biomarker Services
  • 57. LabClinics
  • 58. LabCorp Drug Development
  • 59. Luminex
  • 60. Luxcel Biosciences
  • 61. Massachusetts General Hospital
  • 62. MD Biosciences
  • 63. Millenium Science
  • 64. Millipore Sigma
  • 65. Miltenyi Biotech
  • 66. Miltenyi Imaging (formerly known as Sensovation)
  • 67. MLM Medicine Labs
  • 68. Molecular Device
  • 69. Molecular MD
  • 70. Molecular Pathology Laboratory Network
  • 71. Myriad RBM
  • 72. Namocell
  • 73. NanoCellect Biomedical
  • 74. NanoFCM
  • 75. NeoGenomics Laboratories
  • 76. Nexcelom Bioscience
  • 77. Novogene
  • 78. Omega Biosystem (Acquired by California NanoSystems Institute)
  • 79. Omni Life Science
  • 80. On-Chip Biotechnologies
  • 81. Owl Biomedical
  • 82. Parnassus Flow Cytometry Core facility, University of California
  • 83. PHC Holdings
  • 84. Phitonex (Acquired by Thermofisher Scientific)
  • 85. ProImmune
  • 86. Propel Labs
  • 87. Q2 Solutions
  • 88. QualTek Molecular Laboratories (Acquired by Discovery Life Sciences)
  • 89. RAMCON
  • 90. RayBiotech
  • 91. ReachBio
  • 92. Real Matrix
  • 93. rqmicro
  • 94. Saltro (Acquired by Unilabs)
  • 95. Sartorius Stedim Biotech
  • 96. SBT Instruments
  • 97. Sirigen (Acquired by BD)
  • 98. Sony Biotechnology
  • 99. Stanford University
  • 100. Stratedigm
  • 101. Sumitomo Dainippon Pharma
  • 102. Suzhou Hybiome Biomedical Engineering
  • 103. Sysmex Inostics (Subsidiary of Sysmex)
  • 104. Sysmex Partec
  • 105. Takara Bio
  • 106. Terso Solutions
  • 107. TetraQ
  • 108. Texcell
  • 109. Thermo Fisher Scientific
  • 110. Tomy Digital Biology
  • 111. Unilabs
  • 112. Wyatt Technology
  • 113. Xitogen Technolo